Giulia Cicilese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia Cicilese has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Elena Tamagno
Department of Neuroscience, University of Torino, Via Cherasco 15, 10126 Torino, Italy
1 shared publication - Elisa Porchietto
Department of Neurosciences (Rita Levi Montalcini), University of Turin, 10126 Turin, Italy
1 shared publication - Elisa Rubino
Aging Brain and Memory Clinic, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, 10126 Turin, Italy
1 shared publication - Giulia Morello
Department of Neuroscience, University of Torino, Via Cherasco 15, 10126 Torino, Italy
1 shared publication - Innocenzo Rainero
Aging Brain and Memory Clinic, Department of Neuroscience “Rita Levi Montalcini”, University of Torino, 10126 Turin, Italy
1 shared publication - Michela Guglielmotto
Department of Neuroscience, University of Torino, Via Cherasco 15, 10126 Torino, Italy
1 shared publication
Latest Publications
- Open Access
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9012
UCH-L1 in Alzheimer’s Disease: A Crucial Player in Dementia-Associated Mechanisms
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is a critical deubiquitinating enzyme that is highly expressed in the central nervous system, where it participates in protein degradation and turnover as part of the ubiquitin–proteasome system (UPS). Convincing evidence supports the role of UCH-L1 dysfunction in several neurodegenerative disorders, given its unique position at the crossroad of several aetiopathogenic pathways, including those implicated in Alzheimer’s disease (AD) onset. Indeed, UCH-L1 depletion correlates with decreased levels of triggering receptor expressed on myeloid cells 2 (TREM2), with consequent effects on neuroinflammation. Notably, UCH-L1 can affect the level of phosphorylated tau protein, thus contributing to the formation of neurofibrillary tangles (NFTs). In addition, UCH-L1 influences β-Secretase 1 (BACE1) expression, resulting in the abnormal accumulation of amyloid-β plaques in brain parenchyma. These findings underline UCH-L1’s centrality in maintaining the homeostasis of protein folding and aggregation, which are significantly impaired in AD and AD-related dementias. Given these assumptions, UCH-L1 is recognized as a potential biomarker for AD, highlighting its relevance in governing the fate of crucial pathological mediators of cognitive impairment and neurodegeneration. Herein, we contextualize the involvement of UCH-L1 in different dementia-associated pathways and summarize the state of the art of UCH-L1 as a biomarker for AD diagnosis.
- 16 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9012
Open AccessUCH-L1 in Alzheimer’s Disease: A Crucial Player in Dementia-Associated Mechanisms
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is a critical deubiquitinating enzyme that is highly expressed in the central nervous system, where it participates in protein degradation and turnover as part of the ubiquitin–proteasome system (UPS). Convincing evidence supports the role of UCH-L1 dysfunction in several neurodegenerative disorders, given its unique position at the crossroad of several aetiopathogenic pathways, including those implicated in Alzheimer’s disease (AD) onset. Indeed, UCH-L1 depletion correlates with decreased levels of triggering receptor expressed on myeloid cells 2 (TREM2), with consequent effects on neuroinflammation. Notably, UCH-L1 can affect the level of phosphorylated tau protein, thus contributing to the formation of neurofibrillary tangles (NFTs). In addition, UCH-L1 influences β-Secretase 1 (BACE1) expression, resulting in the abnormal accumulation of amyloid-β plaques in brain parenchyma. These findings underline UCH-L1’s centrality in maintaining the homeostasis of protein folding and aggregation, which are significantly impaired in AD and AD-related dementias. Given these assumptions, UCH-L1 is recognized as a potential biomarker for AD, highlighting its relevance in governing the fate of crucial pathological mediators of cognitive impairment and neurodegeneration. Herein, we contextualize the involvement of UCH-L1 in different dementia-associated pathways and summarize the state of the art of UCH-L1 as a biomarker for AD diagnosis.